comprehensive -WSS

comprehensive

author：explore 2025-09-30 00:09:21 - browse：776

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： CDC recommends RSV monoclonal antibody for infants

hotspot

WSS

CDC recommends RSV monoclonal antibody for infants

A controversial new treatment promises to make little people taller

Feds fine Medicare Advantage plans for overcharging members

AstraZeneca bets AAV gene therapy will still deliver the goods

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Australia’s approach to dialysis celebrates life

focus

comprehensive

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Physicians aren't 'burning out.' They're suffering from moral injury

As demand for Covid shots wanes, Moderna seeks its next success

Florida officials tell state schools to teach AP Psychology 'in its entirety'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC advisory panel says seniors 'may' get RSV vaccine

In age of alternative facts, a scholarly course on calling out crap

2 officers injured in shooting in Orlando, police say

Supreme Court strikes down use of affirmative action

FDA panel gives mixed vote on blood pressure devices

focus

Medicare explains how it will choose drugs for negotiation

FDA panel gives mixed vote on blood pressure devices

Appeals court upholds limits to abortion pill

Psilocybin's anti

Feds fine Medicare Advantage plans for overcharging members

Heart disease in astronauts blamed on cosmic radiation

leisure time

leisure time

hotspot

Wikipedia